Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sangamo Therapeutics Inc

0.7468
+0.04666.66%
Post-market: 0.3900-0.3568-47.78%19:59 EDT
Volume:7.90M
Turnover:5.73M
Market Cap:167.81M
PE:-1.54
High:0.7624
Open:0.6897
Low:0.6874
Close:0.7002
Loading ...

Sangamo: Agreement Grants Lilly Rights to Employ Co's Novel Proprietary Capsid, Stac-Bbb, for up to 5 Potential Disease Targets

THOMSON REUTERS
·
04 Apr

Sangamo Therapeutics Inc: Eligible to Earn up to $1.4 Bln in Additional Licensed Target Fees and Milestone Payments

THOMSON REUTERS
·
04 Apr

Sangamo Therapeutics Inc: Sangamo to Receive an $18 Mln Upfront License Fee

THOMSON REUTERS
·
04 Apr

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

THOMSON REUTERS
·
04 Apr

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

Business Wire
·
04 Apr

Truist Removes Price Target From Sangamo Therapeutics, Keeps Buy Rating; Price Target Had Been $5

MT Newswires Live
·
19 Mar

Sangamo Therapeutics Price Target Maintained With a $2.00/Share by RBC Capital

Dow Jones
·
18 Mar

IHS Holding, HealthEquity And 3 Stocks To Watch Heading Into Tuesday

Benzinga
·
18 Mar

Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
18 Mar

Sangamo Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
18 Mar

Sangamo Therapeutics Q4 2024 GAAP EPS $(0.11) Misses $(0.08) Estimate, Sales $7.551 Miss $13.617M Estimate

Benzinga
·
18 Mar

BRIEF-Sangamo Therapeutics Q4 EPS USD -0.11 Vs. IBES Estimate USD -0.09

Reuters
·
18 Mar

Sangamo Therapeutics Q4 Operating Expenses USD 33.5 Million

THOMSON REUTERS
·
18 Mar

Sangamo options imply 29.8% move in share price post-earnings

TIPRANKS
·
18 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
17 Mar

Sangamo Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Reuters
·
15 Mar

Sangamo Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Reuters
·
07 Mar

Press Release: Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

Dow Jones
·
07 Mar

Sangamo Therapeutics (NASDAQ:SGMO shareholders incur further losses as stock declines 15% this week, taking five-year losses to 89%

Simply Wall St.
·
28 Feb

Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes

Benzinga
·
22 Feb